NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist administered as a subcutaneous injection for the potential treatment of congenital adrenal hyperplasia (CAH).

NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist administered as a subcutaneous injection for the potential treatment of congenital adrenal hyperplasia (CAH).

New indication added for selection of patients for amyloid-directed therapiesQuantitative image analysis addedPrevious limitations of use removed Amyloid, a naturally occurring protein, can accumulate ...

SAN DIEGO, June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, ...

2025 College football Transfer Portal Latest ActivityTransfer Portal Info The 247Sports Transfer Portal includes players who have either announced their intent to enter or have officially entered ...

Everything we know so far about the Chainsaw Man Reze Arc movie, including release date speculation and which manga chapters it could adapt ...

An updated list of release dates for PS5, Xbox Series X|S, Nintendo Switch, and PC games.

Resident Evil Requiem is one of the upcoming horror games we're anticipating, but there's plenty more where that came from ...

Corticotropin-releasing factor (CRF) neuron activity in the medial prefrontal cortex (mPFC) specifically modulates the influence of affective past experience on emotional reactions to others ...